Key result
Homoarginine supplementation in rats with HFpEF did not prevent impairment of diastolic relaxation and increased cardiac fibrosis, but preserved right ventricular function.
Why the study?
Although low homoarginine is associated with diastolic dysfunction in humans, the potential effects of homoarginine supplementation had not yet been tested.
Does homoarginine supplementation improve echocardiographic, histological, and functional parameters of heart and skeletal muscle in a rat model of HFpEF?
RCT (n=12)
Randomized
Does homoarginine supplementation improve echocardiographic, histological, and functional parameters of heart and skeletal muscle in a rat model of HFpEF?
Answers are grounded in this paper and cite their sources.
Homoarginine supplementation in a rat model of HFpEF does not prevent left ventricular or skeletal muscle alterations and increases cardiac fibrosis, though it may preserve right ventricular function.
Aim Heart failure with preserved ejection fraction (HFpEF) is associated with left ventricular stiffness, impaired diastolic relaxation, and severe exercise intolerance. Decreased homoarginine (hArg) levels are an independent predictor of mortality in cardiovascular disease and correlate with impaired exercise performance. We recently reported alterations in arginine, hArg, and related amino acids in obese ZSF1 rats (O-ZSF1), with a HFpEF phenotype. Although low hArg is associated with diastolic dysfunction in humans, potential effects of hArg supplementation were not tested yet. Methods and results At an age of 6 weeks, 12 O-ZSF1 were randomized into two groups: (1) O-ZSF1 rats supplemented with hArg in their drinking water (sO-ZSF1) or (2) O-ZSF1 rats receiving no hArg supplementation (O-ZSF1). At an age of 32 weeks, effects of primary prevention by hArg supplementation on echocardiographic, histological, and functional parameters of heart and skeletal muscle were determined. Lean ZSF1 rats (L-ZSF1) served as controls. hArg supplementation did not prevent impairment of diastolic relaxation (E/e′: O-ZSF1 21 ± 3 vs. sO-ZSF1 22 ± 3, P = 0.954, L-ZSF1 18 ± 5) but resulted in more cardiac fibrosis (histological collagen staining: +57% in sO-ZSF1 vs. O-ZSF1, P = 0.027) and increased collagen gene expression (Col1a1: +48% in sO-ZSF1 vs. O-ZSF1, P = 0.026). In contrary, right ventricular function was preserved by hArg supplementation (TAPSE (mm): O-ZSF1 1.2 ± 0.3 vs. sO-ZSF1 1.7 ± 0.3, P = 0.020, L-ZSF1 1.8 ± 0.4). Musculus soleus maximal specific muscle force (N/cm2) in O-ZSF1 (30.4 ± 0.8) and sO-ZSF1 (31.9 ± 0.9) was comparable but significantly reduced compared with L-ZSF1 (36.4 ± 0.7; both P < 0.05). Maximal absolute muscle force (g) (O-ZSF1: 177.6 ± 7.8, sO-ZSF1: 187.8 ± 5.0, L-ZSF1: 181.5 ± 7.9, all P > 0.05) and cross-sectional fibre area (arbitrary units) (O-ZSF1: 1697 ± 57, sO-ZSF1: 1965 ± 121, L-ZSF1: 1691 ± 104, all P > 0.05) were not altered. Conclusions Preservation of physiological hArg level in HFpEF may not be suited to prevent alterations in left ventricular and skeletal muscle function and structure. However, hArg supplementation may be beneficial for right ventricular function especially in pulmonary hypertension in HFpEF. We may speculate that clinically observed decreased hArg level are not the cause but the consequence of a yet unrecognized pathomechanism that underpins HFpEF.
No takes yet. Share an insight, caveat, or question.
Büttner et al. (2022) conducted an RCT in Heart failure with preserved ejection fraction (HFpEF) (n=12). Homoarginine (hArg) supplementation vs. No hArg supplementation was evaluated on Diastolic relaxation (E/e') (p=0.954). Homoarginine supplementation in rats with HFpEF did not prevent impairment of diastolic relaxation and increased cardiac fibrosis, but preserved right ventricular function.
Synapse has enriched 10 related papers. Consider them for comparative context: